» Authors » Yurie Nagai

Yurie Nagai

Explore the profile of Yurie Nagai including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 42
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakamura A, Kotaki T, Nagai Y, Takazawa S, Tokunaga K, Kameoka M
PLoS One . 2022 Oct; 17(10):e0274829. PMID: 36264936
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a global threat. To forestall the pandemic, developing safe and effective vaccines is...
2.
Kotaki T, Nagai Y, Yamanaka A, Konishi E, Kameoka M
Vaccines (Basel) . 2022 Sep; 10(9). PMID: 36146489
Infection with viruses belonging to the genus , such as Japanese encephalitis virus (JEV) and dengue virus (DENV), is a worldwide health problem. Vaccines against JEV and DENV are currently...
3.
Ishii A, Tsukamoto S, Mishina T, Izumi S, Nagai Y, Yamazaki M, et al.
Leuk Res Rep . 2021 Nov; 16:100278. PMID: 34765438
A 45-year-old woman was diagnosed with myelodysplastic syndrome (MDS) with trisomy 8 and Behçet-like disease (BLD) with multiple colorectal ulcers. Nonspecific inflammatory cells were infiltrated in the intestinal mucosa, whereas...
4.
Mishina T, Oshima-Hasegawa N, Tsukamoto S, Fukuyo M, Kageyama H, Muto T, et al.
Br J Haematol . 2021 Aug; 195(5):731-742. PMID: 34378195
Recent large-scale genetic studies have proposed a new genetic classification of diffuse large B-cell lymphoma (DLBCL), which is clinically and biologically heterogeneous. However, the classification methods were complicated to be...
5.
Kayamori K, Nagai Y, Zhong C, Kaito S, Shinoda D, Koide S, et al.
Blood Adv . 2021 Jan; 5(2):438-450. PMID: 33496740
Dihydroorotate dehydrogenase (DHODH) catalyzes a rate-limiting step in de novo pyrimidine nucleotide synthesis. DHODH inhibition has recently been recognized as a potential new approach for treating acute myeloid leukemia (AML)...
6.
Nagai Y, Mimura N, Rizq O, Isshiki Y, Oshima M, Rizk M, et al.
Sci Rep . 2021 Jan; 11(1):2074. PMID: 33483574
The novel small molecule PTC596 inhibits microtubule polymerization and its clinical development has been initiated for some solid cancers. We herein investigated the preclinical efficacy of PTC596 alone and in...
7.
Zhong C, Kayamori K, Koide S, Shinoda D, Oshima M, Nakajima-Takagi Y, et al.
Cancer Sci . 2020 Oct; 111(12):4336-4347. PMID: 33037737
Monomer tubulin polymerize into microtubules, which are highly dynamic and play a critical role in mitosis. Therefore, microtubule dynamics are an important target for anticancer drugs. The inhibition of tubulin...
8.
Shibamiya A, Ohwada C, Ishii A, Mishina T, Nagai Y, Hino Y, et al.
Bone Marrow Transplant . 2020 Aug; 56(2):517-520. PMID: 32778687
No abstract available.
9.
Nagai Y, Tsukamoto S, Hino Y, Isshiki Y, Yamazaki M, Izumi S, et al.
Leuk Lymphoma . 2019 Sep; 61(1):221-224. PMID: 31486335
No abstract available.
10.
Takaishi K, Tsukamoto S, Ohwada C, Takeuchi M, Kawasaki Y, Nagai Y, et al.
J Thromb Thrombolysis . 2019 Jan; 48(1):141-148. PMID: 30673940
Anti-platelet agents or anticoagulants are administered for patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs) to prevent thrombotic events (TEs). However, there is a discrepancy between current guidelines and...